ArticleJournal of Alzheimer's disease reports
Circulating metabolites mediate the effects of lipids on Alzheimer's disease: A Mendelian randomization and mediation analysis.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although observational studies have reported correlations between lipid, circulating metabolites, and Alzheimer's disease (AD), the causality of these associations remain unresolved. Objective: To investigate the effects of lipids and circulating metabolites on AD risk. Methods: We applied a two-step Mendelian randomization (MR) framework to evaluate the causal effects of lipids on AD and to assess whether these effects are mediated by circulating metabolites. Causal estimates were primarily derived using the inverse-variance weighted method, with robustness evaluated through a series of complementary sensitivity analyses, including Cochran's Q statistic, MR-Egger intercept testing, Radial MR, MR-PRESSO, and leave-one-out analyses. Additional validation was provided by Steiger directionality testing, linkage disequilibrium score regression, multivariable MR analyses, and independent replication, collectively ensuring the reliability of the causal inferences. Results: MR analyses showed that PI(18:1/18:1) and TAG(52:3) were causally associated with a lower risk of AD. Mediation analyses further identified triglyceride levels in low-density lipoproteins (LDL), medium LDL, and small LDL as intermediates, accounting for 17.6%, 22.8%, and 18.1% of the protective effect of PI(18:1/18:1) on AD risk, respectively. By contrast, the free cholesterol to total lipid ratio in medium high-density lipoproteins (HDL) emerged as a deleterious mediator, explaining 13.0% of the protective association between TAG(52:3) and AD. Conclusions: This study highlights the importance of PI(18:1/18:1) and TAG(52:3) in AD development, and suggests that triglyceride levels in LDL, medium LDL, and small LDL, as well as the free cholesterol to total lipids ratio in medium HDL, may act as mediators in this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.